This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Keku, T. O. Articles by Sandler, R. S. Search for Related Content PubMed PubMed Citation Articles by Keku, T. O. Articles by Sandler, R. S. Related Collections Risk Assessment Risk Assessment: Biomarkers

Insulin Resistance, Apoptosis, and Colorectal Adenoma Risk

¹ Department of Medicine and Center for Gastrointestinal Biology and Disease and Departments of ² Cell and Molecular Physiology and ³ Pathology, School of Medicine, University of North Carolina, Chapel Hill, North Carolina

Requests for reprints: Temitope O. Keku, Center for Gastrointestinal Biology and Disease, School of Medicine, University of North Carolina, CB 7555, Chapel Hill, NC 27599-7555. Phone: 919-966-5828; Fax: 919-966-7468. E-mail: tokeku{at}med.unc.edu

Compelling evidence from epidemiologic studies indicates that elevated circulating insulin-like growth factor (IGF)-I, insulin resistance, and associated complications, such as elevated fasting plasma insulin, glucose and free fatty acids, glucose intolerance, increased body mass index, and visceral adiposity, are linked with increased risk of colorectal cancer. However, the role of insulin and markers of glucose control in the development of adenomas, precursors to colorectal cancer, has not been fully explored. We evaluated the relationship between plasma insulin, glucose, IGF-I, IGF-II, IGF-binding protein-3 (IGFBP-3), apoptosis, and colorectal adenomas in a case-control study. Participants were drawn from consenting patients undergoing colonoscopy at the University of North Carolina hospitals (Chapel Hill, NC). Participants were classified as cases or controls based on whether they had one or more colorectal adenomatous polyps. Fasting plasma insulin, IGF-I, IGF-II, and IGFBP-3 levels were assessed by ELISA. Glucose was measured by glucose hexokinase assay. Apoptosis was assessed by morphology on H&E-stained sections. Dietary and lifestyle information were obtained by telephone interview. Logistic regression was used to examine the association between adenoma status and insulin-IGF markers. Adenoma cases (n = 239) and adenoma-free controls (n = 517) provided rectal biopsies and/or blood samples and interview data. Consistent with prior findings, cases were more likely to be males, older, have higher waist-to-hip ratio, lower calcium intake, lower apoptosis, and less likely to report nonsteroidal anti-inflammatory drug use. Those in the highest quartile of insulin (adjusted odds ratio, 2.2; 95% confidence interval, 1.1-4.2) and glucose (adjusted odds ratio, 1.8; 95% confidence interval, 0.9-3.6) were more likely to have an adenoma compared with the lowest quartile. Similarly, subjects in the highest two quartiles of insulin were more likely to be in the lowest two quartiles of apoptosis. Overall, there were no significant differences between mean circulating levels of glucose, IGF-I, IGF-II, and IGFBP-3 among cases and controls and no association between these variables and apoptosis. The results provide novel evidence that elevated insulin and glucose are associated with increased adenoma risk and decreased apoptosis in normal rectal mucosa. These findings suggest that insulin may act early in the adenoma-carcinoma sequence to promote the development of colorectal adenoma by decreasing apoptosis in the normal mucosa.

This article has been cited by other articles:

				D. Landi, F. Gemignani, A. Naccarati, B. Pardini, P. Vodicka, L. Vodickova, J. Novotny, A. Forsti, K. Hemminki, F. Canzian, et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer Carcinogenesis, March 1, 2008; 29(3): 579 - 584. [Abstract] [Full Text] [PDF]

				E. T. Jacobs, M. E. Martinez, D. S. Alberts, E. L. Ashbeck, S. M. Gapstur, P. Lance, and P. A. Thompson Plasma Insulin-Like Growth Factor I Is Inversely Associated with Colorectal Adenoma Recurrence: A Novel Hypothesis Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 300 - 305. [Abstract] [Full Text] [PDF]

				N. M. Ramocki, H. R. Wilkins, S. T. Magness, J. G. Simmons, B. P. Scull, G. H. Lee, K. K. McNaughton, and P. K. Lund Insulin Receptor Substrate-1 Deficiency Promotes Apoptosis in the Putative Intestinal Crypt Stem Cell Region, Limits Apcmin/+ Tumors, and Regulates Sox9 Endocrinology, January 1, 2008; 149(1): 261 - 267. [Abstract] [Full Text] [PDF]

				J. G. Simmons, Y. Ling, H. Wilkins, C. R. Fuller, A. J. D'Ercole, J. Fagin, and P. K. Lund Cell-specific effects of insulin receptor substrate-1 deficiency on normal and IGF-I-mediated colon growth Am J Physiol Gastrointest Liver Physiol, November 1, 2007; 293(5): G995 - G1003. [Abstract] [Full Text] [PDF]

				E. Giovannucci Metabolic syndrome, hyperinsulinemia, and colon cancer: a review Am. J. Clinical Nutrition, September 1, 2007; 86(3): 836S - 842S. [Abstract] [Full Text] [PDF]